<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>MOXATAG- amoxicillinÂ tablet, film coated, extended releaseÂ </strong><br>Pragma Pharmaceuticals, LLC<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use MOXATAG safely and effectively.  See full prescribing information for MOXATAG.   <br><span class="Italics">MOXATAG<span class="Sup">Â®</span></span> (amoxicillin extended-release) Tablets<br>Initial U.S. Approval: 1974
</div>
<div>
<div><p class="Highlighta">To reduce the development of drug-resistant bacteria and maintain the effectiveness of MOXATAG and other antibacterial drugs, MOXATAG should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria. (<a href="#s38">12.4</a>)
 </p></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">MOXATAG is a penicillin-class antibacterial indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> secondary to <span class="Italics">Streptococcus pyogenes</span> in adults and pediatric patients 12 years and older. (<a href="#s1">1</a>)
 </p></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>: 775 mg once daily for 10 days with a meal.
 </p>
<p class="Highlighta">Do not chew or crush tablet. (<a href="#s3">2</a>)
 </p>
</div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><p class="Highlighta">Tablets: 775 mg (<a href="#s4">3</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">Patients with known serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to amoxicillin or to other drugs in the same class or patients who have demonstrated <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to beta-lactams (<a href="#s5">4</a>)
 </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients on penicillin therapy. Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated. (<a href="#s7">5.1</a>)
</li>
<li>
<span class="Italics">Clostridium difficile</span> associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (ranging from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>): Evaluate if <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> occurs.  (<a href="#s8">5.2</a>)
</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<p class="Highlighta">The most common drug-related adverse reactions (incidence â‰¥1.0 %) are vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span> and <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>.  (<a href="#s14">6.1</a>)
 </p>
<p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Fera Pharmaceuticals, LLC at (414) 434-6604 Monday â€“ Friday, 9am-5pm EST, or FDA at 1-800-FDA-1088 or </span><span class="Bold Italics">www.fda.gov/medwatch.</span> </p>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DRUG INTERACTIONS</span></h1>
<div><ul class="Disc"><li>Probenecid decreases the renal tubular secretion of amoxicillin. Concurrent use of amoxicillin and probenecid may result in increased and prolonged blood levels of amoxicillin. (<a href="#s21">7.1</a>)
</li></ul></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>USE IN SPECIFIC POPULATIONS</span></h1>
<div><ul class="Disc">
<li>Pediatrics: The safety and effectiveness of MOXATAG in pediatric patients younger than 12 years has not been established. (<a href="#s29">8.4</a>)
</li>
<li><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>: MOXATAG has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; however a reduction of amoxicillin dose is generally recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. Therefore, MOXATAG is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt; 30 mL/min) or patients on hemodialysis. (<a href="#s31">8.6</a>)
</li>
</ul></div>
<div><div></div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div>
<div></div>
<div><div></div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 6/2015</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc">1.      INDICATIONS AND USAGE
</a></h1>
<h1><a href="#section-2" class="toc">2.      DOSAGE AND ADMINISTRATION
</a></h1>
<h1><a href="#section-3" class="toc">3.      DOSAGE FORMS AND STRENGTHS
</a></h1>
<h1><a href="#section-4" class="toc">4.      CONTRAINDICATIONS
</a></h1>
<h1><a href="#section-5" class="toc">5.      WARNINGS AND PRECAUTIONS
</a></h1>
<h2><a href="#section-5.1" class="toc">5.1    <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</a></h2>
<h2><a href="#section-5.2" class="toc">5.2    Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (CDAD)
</a></h2>
<h2><a href="#section-5.3" class="toc">5.3    <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfections</span>
</a></h2>
<h2><a href="#section-5.4" class="toc">5.4    Mononucleosis <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</a></h2>
<h2><a href="#section-5.5" class="toc">5.5    Development of Drug-Resistant Bacteria
</a></h2>
<h2><a href="#section-5.6" class="toc">5.6    False-Positive Urinary Glucose Tests
</a></h2>
<h1><a href="#section-6" class="toc">6.      ADVERSE REACTIONS
</a></h1>
<h2><a href="#section-6.1" class="toc">6.1    Clinical Study Experience
</a></h2>
<h2><a href="#section-6.2" class="toc">6.2    Adverse Reactions for Other Amoxicillin Products
</a></h2>
<h1><a href="#section-7" class="toc">7.      DRUG INTERACTIONS
</a></h1>
<h2><a href="#section-7.1" class="toc">7.1    Probenecid
</a></h2>
<h2><a href="#section-7.2" class="toc">7.2    Other Antibiotics
</a></h2>
<h2><a href="#section-7.3" class="toc">7.3    Oral Contraceptives
</a></h2>
<h1><a href="#section-8" class="toc">8.      USE IN SPECIFIC POPULATIONS
</a></h1>
<h2><a href="#section-8.1" class="toc">8.1    Pregnancy
</a></h2>
<h2><a href="#section-8.2" class="toc">8.2    Labor and Delivery
</a></h2>
<h2><a href="#section-8.3" class="toc">8.3    Nursing Mothers
</a></h2>
<h2><a href="#section-8.4" class="toc">8.4    Pediatric Use
</a></h2>
<h2><a href="#section-8.5" class="toc">8.5    Geriatric Use
</a></h2>
<h2><a href="#section-8.6" class="toc">8.6    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</a></h2>
<h1><a href="#section-9" class="toc">10.      OVERDOSAGE
</a></h1>
<h1><a href="#section-10" class="toc">11.      DESCRIPTION
</a></h1>
<h1><a href="#section-11" class="toc">12.      CLINICAL PHARMACOLOGY
</a></h1>
<h2><a href="#section-11.1" class="toc">12.1    Mechanism of Action
</a></h2>
<h2><a href="#section-11.2" class="toc">12.3    Pharmacokinetics
</a></h2>
<h2><a href="#section-11.3" class="toc">12.4    Microbiology
</a></h2>
<h1><a href="#section-12" class="toc">13.      NONCLINICAL TOXICOLOGY
</a></h1>
<h2><a href="#section-12.1" class="toc">13.1    Carcinogenesis, Mutagenesis, Impairment of Fertility
</a></h2>
<h1><a href="#section-13" class="toc">14.      CLINICAL STUDIES
</a></h1>
<h1><a href="#section-14" class="toc">15.      REFERENCES
</a></h1>
<h1><a href="#section-15" class="toc">16.      HOW SUPPLIED/STORAGE AND HANDLING
</a></h1>
<h1><a href="#section-16" class="toc">17.      PATIENT COUNSELING INFORMATION
</a></h1>
<h2><a href="#section-16.1" class="toc">17.1    Instructions for Administration of MOXATAG
</a></h2>
<h2><a href="#section-16.2" class="toc">17.2    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</a></h2>
<h2><a href="#section-16.3" class="toc">17.3    Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="dcl-dpl"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="s1"></a><a name="section-1"></a><p></p>
<h1>1.      INDICATIONS AND USAGE
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s2"></a><a name="section-1.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></span></p>
<p>MOXATAG is a penicillin-class antibacterial indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> secondary to <span class="Italics">Streptococcus pyogenes (S.Â pyogenes)</span> in adults and pediatric patients 12 years and older.
</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of MOXATAG and other antibacterial drugs, MOXATAG should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="s3"></a><a name="section-2"></a><p></p>
<h1>2.      DOSAGE AND ADMINISTRATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="e2"></a><a name="section-2.1"></a><p></p>
<p class="First"><span class="Bold"><span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></span></p>
<p>The recommended dose of MOXATAG is 775 mg once daily taken within 1 hour of finishing a meal for 10 days.  The full 10-day course of therapy should be completed for effective treatment of <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> secondary to <span class="Italics">S.Â pyogenes.</span></p>
<p>Do not chew or crush tablet.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="s4"></a><a name="section-3"></a><p></p>
<h1>3.      DOSAGE FORMS AND STRENGTHS
</h1>
<p class="First">775 mg blue film-coated, oval-shaped tablets printed with â€œMB-111â€? on one side in black edible ink.
</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="s5"></a><a name="section-4"></a><p></p>
<h1>4.      CONTRAINDICATIONS
</h1>
<p class="First">MOXATAG is contraindicated in patients with known serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to amoxicillin or to other drugs in the same class or patients who have demonstrated <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> to beta-lactams.
</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="s6"></a><a name="section-5"></a><p></p>
<h1>5.      WARNINGS AND PRECAUTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s7"></a><a name="section-5.1"></a><p></p>
<h2>5.1    <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> and <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</h2>
<p class="First">Serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported in patients on penicillin therapy. Although <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> and/or a history of sensitivity to multiple allergens. There have been reports of individuals with a history of penicillin <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> who have experienced severe reactions when treated with cephalosporins. Before initiating therapy with MOXATAG, careful inquiry should be made concerning previous <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to penicillins, cephalosporins, or other allergens. If an <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> occurs, MOXATAG should be discontinued and appropriate therapy instituted.
</p>
<p><span class="Bold">Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine. Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s8"></a><a name="section-5.2"></a><p></p>
<h2>5.2    Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (CDAD)
</h2>
<p class="First"><span class="Italics">Clostridium difficile</span> Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> (CDAD) has been reported with nearly all antibacterial agents, including amoxicillin, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of <span class="Italics">C. difficile</span>.
</p>
<p><span class="Italics">C. difficile</span> produces toxins A and B which contribute to the development of CDAD. Hypertoxin-producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">C. difficile</span> cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents.
</p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against <span class="Italics">C. difficile</span> may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of <span class="Italics">C.Â difficile</span>, and surgical evaluation should be instituted as clinically indicated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s9"></a><a name="section-5.3"></a><p></p>
<h2>5.3    <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">Superinfections</span>
</h2>
<p class="First">The possibility of <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> with mycotic or bacterial pathogens should be kept in mind during therapy. If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfections</span> occur, amoxicillin should be discontinued and appropriate therapy instituted.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s10"></a><a name="section-5.4"></a><p></p>
<h2>5.4    Mononucleosis <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">Rash</span>
</h2>
<p class="First">A high percentage of patients with mononucleosis who receive ampicillin develop an erythematous <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">skin rash</span>.  Thus, ampicillin-class antibiotics should not be administered to patients with mononucleosis.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s11"></a><a name="section-5.5"></a><p></p>
<h2>5.5    Development of Drug-Resistant Bacteria
</h2>
<p class="First">Prescribing amoxicillin in the absence of proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or treating prophylactically is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s12"></a><a name="section-5.6"></a><p></p>
<h2>5.6    False-Positive Urinary Glucose Tests
</h2>
<p class="First">High urine concentrations of ampicillin may result in false-positive reactions when testing for the presence of glucose in urine using ClinitestÂ®, Benedict's Solution or Fehling's Solution. Since this effect may also occur with amoxicillin, it is recommended that glucose tests based on enzymatic glucose oxidase reactions (such as ClinistixÂ®) be used.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="s13"></a><a name="section-6"></a><p></p>
<h1>6.      ADVERSE REACTIONS
</h1>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14"></a><a name="section-6.1"></a><p></p>
<h2>6.1    Clinical Study Experience
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s15"></a><a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span></span></p>
<p>In a controlled Phase 3 trial, 302 adult and pediatric patients (â‰¥12 years) were treated with MOXATAG 775 mg once-daily for 10 days and 306 adult and pediatric patients (â‰¥12 years) were treated with penicillin VK 250 mg QID for 10 days.
</p>
<p>In this clinical trial, the majority of treatment-emergent adverse reactions were of a mild and transient nature with similar frequency reported in both treatment groups. Discontinuation due to drug-related treatment-emergent adverse reactions occurred in 1.3% of the MOXATAG-treated patients and 3.3% of the penicillin VK-treated patients.
</p>
<p>The most frequently reported adverse reactions (â‰¥1%) which were suspected or probably drug-related are shown in <a href="#t1">Table 1</a>.
</p>
<a name="t1"></a><table width="100%">
<caption><span>Table 1. Â Drug-Related Treatment-Emergent Adverse Reactions by System Organ Class Experienced by â‰¥1% of Patients in Either Treatment Group â€“ ITT/Safety Population
</span></caption>
<col align="left" width="55.400%">
<col align="left" width="22.600%">
<col align="left" width="22.000%">
<tfoot><tr class="First Last"><td align="left" colspan="3" valign="top"><p class="First Footnote">*Presented in decreasing order of frequency in the MOXATAG column within each system organ class.
</p></td></tr></tfoot>
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"></td>
<td class="Botrule" align="center" colspan="2" valign="top">Number (%) of patients
</td>
</tr>
<tr>
<td class="Botrule" align="center" valign="top">System Organ Class/Preferred Term*
</td>
<td class="Botrule" align="center" valign="top">MOXATAG<br>(N =302)
</td>
<td class="Botrule" align="center" valign="top">Penicillin VK<br>(N = 306 )
</td>
</tr>
<tr>
<td align="left" valign="top">Patients with at least one drug-related treatment-emergent adverse event
</td>
<td align="center" valign="top">32 (10.6)
</td>
<td align="center" valign="top">45 (14.7)
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">infestations</span>
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â  Â  Vulvovaginal mycotic <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>
</td>
<td align="center" valign="top">6 (2.0)
</td>
<td align="center" valign="top">8 (2.6)
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal disorders</span>
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</td>
<td align="center" valign="top">5 (1.7)
</td>
<td align="center" valign="top">6 (2.0)
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>
</td>
<td align="center" valign="top">4 (1.3)
</td>
<td align="center" valign="top">2 (0.7)
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Vomiting</span>
</td>
<td align="center" valign="top">2 (0.7)
</td>
<td align="center" valign="top">5 (1.6)
</td>
</tr>
<tr>
<td align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">Abdominal pain</span>
</td>
<td align="center" valign="top">1 (0.3)
</td>
<td align="center" valign="top">3 (1.0)
</td>
</tr>
<tr>
<td align="left" valign="top"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous system disorders</span>
</td>
<td align="center" valign="top"></td>
<td align="center" valign="top"></td>
</tr>
<tr class="Last">
<td class="Botrule" align="left" valign="top">Â  Â  Â <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span>
</td>
<td class="Botrule" align="center" valign="top">3 (1.0)
</td>
<td class="Botrule" align="center" valign="top">3 (1.0)
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s16"></a><a name="section-6.2"></a><p></p>
<h2>6.2    Adverse Reactions for Other Amoxicillin Products
</h2>
<p class="First">The following adverse reactions have been reported for other products containing amoxicillin:
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s17"></a><a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> and <span class="product-label-link" type="condition" conceptid="432251" conceptname="Disease caused by parasite">Infestations</span></span>: <span class="product-label-link" type="condition" conceptid="4104522" conceptname="Mucocutaneous candidiasis">Mucocutaneous candidiasis</span>.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s18"></a><a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Italics Underline">Gastrointestinal</span>: <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, and hemorrhagic/<span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span>.
</p>
<p>Onset of <span class="product-label-link" type="condition" conceptid="4265457" conceptname="Pseudomembranous enterocolitis">pseudomembranous colitis</span> symptoms may occur during or after antibiotic treatment.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s19"></a><a name="section-6.2.3"></a><p></p>
<p class="First"><span class="Italics Underline"><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span></span>: <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">Anaphylaxis</span> (See Warnings and Precautions).
</p>
<p><span class="product-label-link" type="condition" conceptid="432522" conceptname="Transfusion reaction due to serum protein reaction">Serum sickness</span> like reactions, erythematous <span class="product-label-link" type="condition" conceptid="4083795" conceptname="Maculopapular eruption">maculopapular rashes</span>, <span class="product-label-link" type="condition" conceptid="132702" conceptname="Erythema multiforme">erythema multiforme</span>, <span class="product-label-link" type="condition" conceptid="141651" conceptname="Stevens-Johnson syndrome">Stevens-Johnson Syndrome</span>, exfoliative  <span class="product-label-link" type="condition" conceptid="133835" conceptname="Eczema">dermatitis</span>, <span class="product-label-link" type="condition" conceptid="443754" conceptname="Lyell's toxic epidermal necrolysis, subepidermal type">toxic epidermal necrolysis</span>, <span class="product-label-link" type="condition" conceptid="45773387" conceptname="Acute generalized exanthematous pustulosis">acute generalized exanthematous pustulosis</span>, <span class="product-label-link" type="condition" conceptid="196431" conceptname="Hypersensitivity angiitis">hypersensitivity vasculitis</span> and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span> have been reported. (NOTE: These <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> may be controlled with antihistamines and, if necessary, systemic corticosteroids. Whenever such reactions occur, amoxicillin should be discontinued unless, in the opinion of the physician, the condition being treated is life-threatening and amenable only to amoxicillin therapy.)
</p>
<p><span class="Italics">Liver:</span> A moderate rise in AST (<span class="product-label-link" type="condition" conceptid="4094657" conceptname="Aspartate aminotransferase">SGOT</span>) and/or ALT (SGPT) has been noted, but the significance of this finding is unknown. Hepatic dysfunction including <span class="product-label-link" type="condition" conceptid="4185719" conceptname="Cholestatic jaundice syndrome">cholestatic jaundice</span>, hepatic <span class="product-label-link" type="condition" conceptid="4143915" conceptname="Cholestasis">cholestasis</span> and <span class="product-label-link" type="condition" conceptid="194990" conceptname="Inflammatory disease of liver">acute cytolytic hepatitis</span> have been reported.
</p>
<p><span class="Italics">Hemic and Lymphatic Systems:</span> <span class="product-label-link" type="condition" conceptid="439777" conceptname="Anemia">Anemia</span>, including <span class="product-label-link" type="condition" conceptid="435503" conceptname="Hemolytic anemia">hemolytic anemia</span>, <span class="product-label-link" type="condition" conceptid="432870" conceptname="Thrombocytopenic disorder">thrombocytopenia</span>, <span class="product-label-link" type="condition" conceptid="4119134" conceptname="Thrombocytopenic purpura">thrombocytopenic purpura</span>, <span class="product-label-link" type="condition" conceptid="4302954" conceptname="Disorder characterized by eosinophilia">eosinophilia</span>, <span class="product-label-link" type="condition" conceptid="435224" conceptname="Leukopenia">leukopenia</span>, and <span class="product-label-link" type="condition" conceptid="440689" conceptname="Agranulocytosis">agranulocytosis</span> have been reported during therapy with penicillins.  These reactions are usually reversible on discontinuation of therapy and are believed to be <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> phenomena.
</p>
<p><span class="Italics">Central Nervous System:</span> Reversible <span class="product-label-link" type="condition" conceptid="4137162" conceptname="Overactive">hyperactivity</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">convulsions</span>, behavioral changes, and/or <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> have been reported rarely.
</p>
<p><span class="Italics">Renal:</span> <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span> has also been reported.
</p>
<p><span class="Italics">Miscellaneous:</span> <span class="product-label-link" type="condition" conceptid="45757361" conceptname="Mottled teeth">Tooth discoloration</span> (brown, yellow, or gray staining) has been rarely reported.  Most reports occurred in pediatric patients.  Discoloration was reduced or eliminated with brushing or dental cleaning in most cases.
</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="s20"></a><a name="section-7"></a><p></p>
<h1>7.      DRUG INTERACTIONS
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s21"></a><a name="section-7.1"></a><p></p>
<h2>7.1    Probenecid
</h2>
<p class="First">Probenecid decreases the renal tubular secretion of amoxicillin.  Concurrent use of MOXATAG and probenecid may result in increased and prolonged blood levels of amoxicillin.  The clinical relevance of this finding has not been evaluated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s22"></a><a name="section-7.2"></a><p></p>
<h2>7.2    Other Antibiotics
</h2>
<p class="First">Chloramphenicol, macrolides, sulfonamides, and tetracyclines may interfere with the bactericidal effects of penicillin.  This has been demonstrated <span class="Italics">in vitro</span>; however, the clinical significance of this interaction is not well documented.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s23"></a><a name="section-7.3"></a><p></p>
<h2>7.3    Oral Contraceptives
</h2>
<p class="First">As with other antibiotics, amoxicillin may affect the gut flora, leading to lower estrogen reabsorption and potentially resulting in reduced efficacy of combined oral estrogen/progesterone contraceptives.
</p>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="s24"></a><a name="section-8"></a><p></p>
<h1>8.      USE IN SPECIFIC POPULATIONS
</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="s25"></a><a name="section-8.1"></a><p></p>
<h2>8.1    Pregnancy
</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="s26"></a><a name="section-8.1.1"></a><p></p>
<p class="First"><span class="Bold">Teratogenic Effects.  Pregnancy Category B.</span>  Reproduction studies have been performed in mice and rats at doses up to 2000 mg/kg (12.5 and 25 times the human dose in mg/m<span class="Sup">2</span>) and have revealed no evidence of impaired fertility or harm to the fetus due to amoxicillin.  There are, however, no adequate and well-controlled studies in pregnant women.  Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34079-4">
<a name="s27"></a><a name="section-8.2"></a><p></p>
<h2>8.2    Labor and Delivery
</h2>
<p class="First">Oral ampicillin-class antibiotics are poorly absorbed during labor. Studies in guinea pigs showed that intravenous administration of ampicillin slightly decreased the uterine tone and frequency of contractions but moderately increased the height and duration of contractions.  However, it is not known whether use of amoxicillin in humans during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor, or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.
</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="s28"></a><a name="section-8.3"></a><p></p>
<h2>8.3    Nursing Mothers
</h2>
<p class="First">Penicillins have been shown to be excreted in human milk. Amoxicillin use by nursing mothers may lead to sensitization of infants.  Caution should be exercised when amoxicillin is administered to a nursing woman.
</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="s29"></a><a name="section-8.4"></a><p></p>
<h2>8.4    Pediatric Use
</h2>
<p class="First">The safety and effectiveness of MOXATAG in pediatric patients 12Â years of age and older have been established based on results of a clinical trial that included adults and pediatric patients (12 years and older). [see <span class="Italics">Clinical Studies</span> (<a href="#s46">14</a>)]  Sixty-three (21%) of the study participants were pediatric patients 12 years of age and older.  There were no significant differences in treatment response or adverse reactions from adults.
</p>
<p>The safety and effectiveness of MOXATAG in pediatric patients younger than 12 years has not been established.
</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="s30"></a><a name="section-8.5"></a><p></p>
<h2>8.5    Geriatric Use
</h2>
<p class="First">Clinical studies with MOXATAG did not include a sufficient number of patients aged 65 years and over to determine whether they respond differently from younger patients.  Other reported clinical experiences with amoxicillin have not yet identified differences in responses between the elderly and younger patients, but a greater sensitivity of some older individuals cannot be ruled out.
</p>
<p>This drug is known to be substantially excreted by the kidneys, and the risk of adverse reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>.  Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s31"></a><a name="section-8.6"></a><p></p>
<h2>8.6    <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal Impairment</span>
</h2>
<p class="First">MOXATAG has not been studied in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>; however, a reduction of amoxicillin dose is generally recommended for patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>.  Therefore, MOXATAG is not recommended for use in patients with severe <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span> (CrCl &lt;30 mL/min) or patients on hemodialysis.
</p>
</div>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="s32"></a><a name="section-9"></a><p></p>
<h1>10.      OVERDOSAGE
</h1>
<p class="First">In case of <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span>, discontinue medication, treat symptomatically, and institute supportive measures as required.  If the <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> is very recent and there is no contraindication, an attempt at <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">emesis</span> or other means of removal of drug from the stomach may be performed.  A prospective study of 51 pediatric patients at a poison-control center suggested that overdosages of less than 250 mg/kg of amoxicillin are not associated with significant clinical symptoms and do not require gastric emptying.
</p>
<p>Interstitial <span class="product-label-link" type="condition" conceptid="193253" conceptname="Nephritis">nephritis</span> resulting in oliguric <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span> has been reported in a small number of patients after overdosage with amoxicillin.
</p>
<p><span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">Crystalluria</span>, in some cases leading to <span class="product-label-link" type="condition" conceptid="192359" conceptname="Renal failure syndrome">renal failure</span>, has also been reported after amoxicillin overdosage in adult and pediatric patients.  In case of overdosage, adequate fluid intake and <span class="product-label-link" type="condition" conceptid="79936" conceptname="Polyuria">diuresis</span> should be maintained to reduce the risk of amoxicillin <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>.
</p>
<p><span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">Renal impairment</span> appears to be reversible with cessation of drug administration.  High blood levels may occur more readily in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span> because of decreased renal clearance of amoxicillin.  Amoxicillin may be removed from circulation by hemodialysis.
</p>
<p> For additional information about <span class="product-label-link" type="condition" conceptid="4208104" conceptname="Drug overdose">overdose</span> treatment, call a poison control center (1-800-222-1222).
</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="s33"></a><a name="section-10"></a><p></p>
<h1>11.      DESCRIPTION
</h1>
<p class="First">MOXATAG (amoxicillin extended-release) tablets for oral administration are provided as blue film-coated, oval shaped tablets that contain 775 mg of amoxicillin as the trihydrate and are printed with â€?MB-111â€? on one side in black edible ink.
</p>
<p>Amoxicillin is a semi-synthetic antibiotic, an analog of ampicillin, with bactericidal activity against gram-positive and gram-negative microorganisms.
</p>
<p>Chemically, amoxicillin is (2 <span class="Italics">S</span>,5 <span class="Italics">R</span>,6 <span class="Italics">R</span>)-6-[(R)-(-)-2-amino-2-(<span class="Italics">p</span>-hydroxyphenyl) acetamido]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid trihydrate. Its chemical name is amoxicillin.  It may be represented structurally as:
</p>
<div class="Figure">
<a name="f01"></a><img alt="Structural Formula
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4057faf7-6d45-4d9e-90e9-72a546214d04&amp;name=mox02-0001-01.jpg">
</div>
<p>The amoxicillin molecular formula is C<span class="Sub">16</span>H<span class="Sub">19</span>N<span class="Sub">3</span>O<span class="Sub">5</span>SÂ·3H<span class="Sub">2</span>O, and the molecular weight is 419.45.
</p>
<p>MOXATAG is an extended release tablet formulation consisting of three components, one immediate-release and two delayed-release, each containing amoxicillin.  The three components are combined in a specific ratio to prolong the release of amoxicillin from MOXATAG compared to immediate-release amoxicillin.
</p>
<p>Each tablet contains amoxicillin, crospovidone, FD&amp;C Blue #2 lake, hypromellose, hypromellose acetate succinate, iron oxide, magnesium stearate, methacrylic acid copolymer, microcrystalline cellulose, polyethylene glycol 400, polyoxyl 35 castor oil, povidone, shellac, colloidal silicon dioxide, sodium lauryl sulfate, talc, titanium dioxide, and triethyl citrate.
</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="s34"></a><a name="section-11"></a><p></p>
<h1>12.      CLINICAL PHARMACOLOGY
</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="s35"></a><a name="section-11.1"></a><p></p>
<h2>12.1    Mechanism of Action
</h2>
<p class="First">Amoxicillin is an antibacterial drug. [see <span class="Italics">Clinical Pharmacology</span> (<a href="#s38">12.4</a>)]
</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="s36"></a><a name="section-11.2"></a><p></p>
<h2>12.3    Pharmacokinetics
</h2>
<p class="First">MOXATAG is an extended-release formulation of amoxicillin intended to provide once-daily dosing.  Following the administration of MOXATAG with a low-fat meal in healthy subjects, mean amoxicillin AUC<span class="Sub">0-âˆž</span>, C<span class="Sub">max</span>, and T<span class="Sub">max</span> values were 29.8 Î¼gâ€¢h/mL, 6.6 Î¼g/mL and 3.1 hours, respectively.  The mean plasma concentration-time curve is shown below in <a href="#fig1">Figure 1</a>.
</p>
<p><a name="fig1"></a>Figure 1. Mean Amoxicillin Plasma Concentrations Following a Single Oral Dose of MOXATAG With a Low-Fat Meal in Healthy Subjects (N=20)
</p>
<div class="Figure">
<a name="f02"></a><img alt="Figure 1
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4057faf7-6d45-4d9e-90e9-72a546214d04&amp;name=mox02-0001-02.jpg">
</div>
<p>Administration of MOXATAG with food decreases the rate, but not the extent of amoxicillin absorption.  Compared to immediate-release amoxicillin suspension, the rate of amoxicillin absorption following administration of MOXATAG was slower, resulting in a lower C<span class="Sub">max</span> and longer T<span class="Sub">max</span>.  Total amoxicillin exposure (AUC) achieved with MOXATAG is similar to that observed after oral administration of a comparable dose of immediate-release amoxicillin suspension.
</p>
<p> Amoxicillin diffuses readily into most body tissues and fluids, with the exception of brain and spinal fluid, except when meninges are inflamed.  Amoxicillin is approximately 20% protein bound in human serum.
</p>
<p>Amoxicillin is primarily cleared by renal excretion.  Approximately 60% of an oral dose of immediate-release amoxicillin is eliminated unchanged in urine.  The half-life of amoxicillin after oral administration of MOXATAG is approximately 1.5 hours, similar to that of immediate-release amoxicillin.  No accumulation of amoxicillin was observed after once-daily dosing of 775 mg of MOXATAG for 7Â days.
</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s37"></a><a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Bold">Drug Interactions</span></p>
<p> In a study of healthy adult subjects, amoxicillin AUC was similar whereas C<span class="Sub">max</span> increased approximately 35% following the administration of lansoprazole with MOXATAG given with food.
</p>
<p> Probenecid decreases the renal tubular secretion of amoxicillin.  Concurrent use of MOXATAG and probenecid may result in increased and prolonged blood levels of amoxicillin.  The clinical relevance of this finding has not been evaluated.
</p>
</div>
</div>
<div class="Section" data-sectionCode="49489-8">
<a name="s38"></a><a name="section-11.3"></a><p></p>
<h2>12.4    Microbiology
</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="s39"></a><a name="section-11.3.1"></a><p></p>
<p class="First"><span class="Bold">Mechanism of Action</span></p>
<p>Amoxicillin is similar to penicillin in its bacterial action against susceptible organisms during the stage of active multiplication.  It acts through the inhibition of cell wall biosynthesis that leads to the <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the bacteria.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s40"></a><a name="section-11.3.2"></a><p></p>
<p class="First"><span class="Bold">Mechanism of Resistance</span></p>
<p>To date there are no known mechanisms of resistance to penicillin or amoxicillin in <span class="Italics">Streptococcus pyogenes.</span></p>
<p><span class="Bold">Antimicrobial Activity</span></p>
<p>Amoxicillin has been shown to be active <span class="Italics">in vitro</span> against isolates of the microorganism <span class="Italics">S. pyogenes</span> and in clinical <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> as described in the INDICATIONS AND USAGE section.
</p>
<p><span class="Bold">Gram-Positive Bacteria:</span></p>
<p><span class="Italics">Streptococcus pyogenes</span></p>
<p>The following <span class="Italics">in vitro</span> data are available, but their clinical significance is unknown.  At least 90% of the following microorganisms exhibit an <span class="Italics">in vitro</span> <span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">minimum inhibitory concentration</span> (MIC) less than or equal to the susceptibility breakpoint of amoxicillin (as determined by susceptibility tests using the class representative agents penicillin or ampicillin).
</p>
<p><span class="Bold">Gram-Positive Bacteria:</span></p>
<p><span class="Italics">Streptococcus</span> spp. (Group B, C, and G; Beta-hemolytic)
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s41"></a><a name="section-11.3.3"></a><p></p>
<p class="First"><span class="Bold">Susceptibility Test Methods:</span></p>
<p>When available, the clinical microbiology laboratory should provide cumulative <span class="Italics">in vitro</span> susceptibility test results for antimicrobial drugs used in local hospitals and practice areas to the physician as periodic reports that describe the susceptibility profile of nosocomial and community-acquired pathogens.  These reports should aid the physician in selecting the most effective antimicrobial.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s42"></a><a name="section-11.3.4"></a><p></p>
<p class="First"><span class="Bold">Dilution Techniques</span></p>
<p>Quantitative methods are used to determine antimicrobial MICs.  These MICs provide estimates of the susceptibility of bacteria to antimicrobial compounds.  The MICs should be determined using a standardized method (broth or agar)<span class="Sup">1,2</span>.
</p>
<p>Susceptibility of beta-hemolytic streptococcal isolates to amoxicillin may be inferred by testing penicillin.  An organism that is susceptible to penicillin can be considered susceptible to amoxicillin when used for approved indications<span class="Sup">2</span>.  If testing is performed, any beta hemolytic streptococcal isolate found to be nonsusceptible should be reidentified, retested, and if confirmed, submitted to a public health laboratory.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s43"></a><a name="section-11.3.5"></a><p></p>
<p class="First"><span class="Bold">Quality Control</span></p>
<p>Standardized susceptibility test procedures<span class="Sup">1,2</span> require the use of laboratory controls to monitor and ensure the accuracy and precision of the supplies and reagents used in the assay, and the techniques of the individuals performing the test. Standard amoxicillin powder should provide the following range of MIC values provided in <a href="#t2">Table 2</a><span class="Sup">2</span>.
</p>
<a name="t2"></a><table width="100%">
<caption><span>Table 2. Acceptable Quality Control Ranges for Amoxicillin<span class="Sup">a</span></span></caption>
<col align="left" width="37.300%">
<col align="left" width="30.500%">
<col align="left" width="32.200%">
<tfoot>
<tr class="First"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">a</span>QC limits for testing <span class="Italics">E. coli</span> 35218 when tested on Haemophilus Test Medium (HTM) are greater than 256 mcg/mL for amoxicillin; testing amoxicillin may help to determine if the isolate has maintained its ability to produce beta-lactamase<span class="Sup">2</span>.
</p></td></tr>
<tr class="Last"><td align="left" colspan="3" valign="top"><p class="First Footnote"><span class="Sup">b</span>ATCC = American Type Culture Collection
</p></td></tr>
</tfoot>
<tbody class="Headless">
<tr class="First">
<td class="Botrule" align="center" valign="middle">Quality Control Organism
</td>
<td class="Botrule" align="center" valign="bottom"><span class="product-label-link" type="condition" conceptid="4190299" conceptname="Broth microdilution susceptibility test">Minimum Inhibitory Concentrations</span> (mcg/mL)
</td>
<td class="Botrule" align="center" valign="bottom">Disk Diffusion Zone<br>Diameters<br>(mm)
</td>
</tr>
<tr>
<td class="Botrule" align="left" valign="middle">
<span class="Italics">Streptococcus pneumoniae</span><br>ATCC<span class="Sup">b</span> 49619
</td>
<td class="Botrule" align="center" valign="middle">0.03â€“0.12
</td>
<td class="Botrule" align="center" valign="middle">---
</td>
</tr>
<tr class="Last">
<td align="left" valign="middle">
<span class="Italics">Klebsiella pneumoniae</span><br>ATCC 700603
</td>
<td align="center" valign="middle">&gt;128
</td>
<td align="center" valign="middle">---
</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="s44"></a><a name="section-12"></a><p></p>
<h1>13.      NONCLINICAL TOXICOLOGY
</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="s45"></a><a name="section-12.1"></a><p></p>
<h2>13.1    Carcinogenesis, Mutagenesis, Impairment of Fertility
</h2>
<p class="First">Long-term studies in animals have not been performed to evaluate carcinogenic potential. Studies to detect mutagenic potential of amoxicillin alone have not been conducted; however, the following information is available from tests on a 4:1 mixture of amoxicillin and potassium clavulanate (<span class="Italics">Augmentin</span>).  <span class="Italics">Augmentin</span> was non-mutagenic in the Ames bacterial mutation assay, and the yeast gene conversion assay.  <span class="Italics">Augmentin</span> was weakly positive in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> assay, but the trend toward increased mutation frequencies in this assay occurred at doses that were also associated with decreased cell survival.  <span class="Italics">Augmentin</span> was negative in the mouse micronucleus test, and in the dominant lethal assay in mice.  Potassium clavulanate alone was tested in the Ames bacterial mutation assay and in the mouse micronucleus test, and was negative in each of these assays.  In a multi-generation reproduction study in rats, no impairment of fertility or other adverse reproductive effects were seen at doses up to 500 mg/kg (approximately 6 times the human dose in mg/m<span class="Sup">2</span>).
</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="s46"></a><a name="section-13"></a><p></p>
<h1>14.      CLINICAL STUDIES
</h1>
<p class="First">In a randomized, parallel-group, multi-center, double-blind, double-dummy study in adults and pediatrics (age â‰¥ 12 years) with <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> secondary to <span class="Italics">S. pyogenes,</span> MOXATAG 775 mg QD for 10 days was non-inferior to penicillin VK 250 mg QID for 10 days.
</p>
<p>Using strict evaluability and microbiologic response criteria 4-8 days post-therapy, the following bacteriological eradication rates and statistical outcomes in the per-protocol (PPb) and modified intent-to-treat (mITT) populations were obtained (<a href="#t3">Table 3</a>).  The mITT population included all randomized patients with a positive throat culture for <span class="Italics">S. pyogenes</span> at baseline.  The PPb population included mITT patients who had post-therapy cultures, were compliant with treatment, and didn't have major protocol violations.
</p>
<a name="t3"></a><table width="100%">
<caption><span>Table 3. Bacteriological Eradication Rates in Patients with <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">Tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">Pharyngitis</span>
</span></caption>
<col align="left" width="23.681%">
<col align="left" width="23.681%">
<col align="left" width="23.681%">
<col align="left" width="28.957%">
<tbody class="Headless">
<tr class="First">
<td align="center" valign="top"><span class="Bold">Study Population</span></td>
<td align="center" valign="top"><span class="Bold">MOXATAG</span></td>
<td align="center" valign="top"><span class="Bold">Penicillin VK</span></td>
<td align="center" valign="top"><span class="Bold">Rate Difference 95% CI (%)</span></td>
</tr>
<tr>
<td align="center" valign="top">PPb
</td>
<td align="center" valign="top">198/233<br>(85.0%)
</td>
<td align="center" valign="top">191/229<br>(83.4%)
</td>
<td align="center" valign="top">1.6 (-5.1, 8.2)
</td>
</tr>
<tr class="Last">
<td align="center" valign="top">mITT
</td>
<td align="center" valign="top">204/256<br>(79.7%)
</td>
<td align="center" valign="top">206/264<br>(78.0%)
</td>
<td align="center" valign="top">1.7 (-5.4, 8.7)
</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="s47"></a><a name="section-14"></a><p></p>
<h1>15.      REFERENCES
</h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically; Approved Standard â€“ Tenth Edition</span>. CLSI document M07-A10, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
</li>
<li>Clinical and Laboratory Standards Institute (CLSI). <span class="Italics">Performance Standards for Antimicrobial Susceptibility Testing; Twenty-fifth Informational Supplement</span>, CLSI document M100-S25, Clinical and Laboratory Standards Institute, 950 West Valley Road, Suite 2500, Wayne, Pennsylvania 19087, USA, 2015.
</li>
</ol>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="s48"></a><a name="section-15"></a><p></p>
<h1>16.      HOW SUPPLIED/STORAGE AND HANDLING
</h1>
<p class="First">MOXATAG tablets for oral administration are provided as blue film-coated, oval-shaped tablets that contain 775 mg of amoxicillin as the trihydrate.  The tablets are printed with â€œMB-111â€? on one side in black edible ink.  MOXATAG is packaged in bottles as follows:
</p>
<p>Bottles of 30Â  Â  Â  Â NDC 58463-002-30
</p>
<div class="Section" data-sectionCode="44425-7">
<a name="s49"></a><a name="section-15.1"></a><p></p>
<p class="First"><span class="Bold">Storage</span></p>
<p>Store at 25Âº C (77Âº F); excursions permitted to 15Â°â€“30Âº C (59Â°â€“86Âº F) [See USP Controlled Room Temperature.]
</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="s50"></a><a name="section-16"></a><p></p>
<h1>17.      PATIENT COUNSELING INFORMATION
</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s51"></a><a name="section-16.1"></a><p></p>
<h2>17.1    Instructions for Administration of MOXATAG
</h2>
<p class="First">Patients should be informed that the recommended dose of MOXATAG is 775 mg once daily taken with food for 10 days.  MOXATAG should be taken within 1 hour of finishing a meal and at approximately the same time every day.  The full 10-day course of therapy should be completed for effective treatment of <span class="product-label-link" type="condition" conceptid="4234533" conceptname="Tonsillitis">tonsillitis</span> and/or <span class="product-label-link" type="condition" conceptid="4226263" conceptname="Pharyngitis">pharyngitis</span> secondary to <span class="Italics">S.Â pyogenes.</span>    Patients should be instructed not to chew or crush the tablet.  No other forms of immediate-release amoxicillin can be substituted for MOXATAG.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s52"></a><a name="section-16.2"></a><p></p>
<h2>17.2    <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity Reactions</span>
</h2>
<p class="First">Patients should be informed that serious and occasionally fatal <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> (anaphylactic) reactions have been reported while on penicillin therapy.   Patients should be questioned regarding any <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to penicillins, cephalosporins or other allergens.  Whenever such reactions occur, the patient should be instructed to contact their physician immediately.  Serious <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reactions</span> require immediate emergency treatment with epinephrine.  Oxygen, intravenous steroids, and airway management, including intubation, should also be administered as indicated.
</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s53"></a><a name="section-16.3"></a><p></p>
<h2>17.3    Clostridium difficile Associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span>
</h2>
<p class="First">Patients should be informed that <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued.  Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic.  If this occurs, patients should contact their physician as soon as possible.
</p>
<p>AUGMENTIN is a registered trademark of GlaxoSmithKline.<br>CLINITEST is a registered trademark of Miles, Inc.<br>CLINISTIX is a registered trademark of Bayer Corporation.<br>MOXATAG is a registered trademark of Pragma Pharmaceuticals, LLC all rights reserved.
</p>
<p>Manufactured in Ireland for:<br>Pragma Pharmaceuticals, LLC
</p>
<p>Distributed by:<br>Fera Pharmaceuticals, LLC, Locust Valley, NY, 11560
</p>
<p>U.S. Patents 6,544,555; 6,669,948; 6,723,341
</p>
<p>Rev 06/15<br>PPL-002
</p>
</div>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="s54"></a><a name="section-17"></a><p></p>
<p class="First"><span class="Bold">Principal Display Panel - Bottle Label</span></p>
<p>NDC 58463-002-30
</p>
<p><span class="Bold">30 tablets</span></p>
<p><span class="Bold">moxatag<span class="Sup">Â®</span><br></span>(amoxicillin extended-release tablets)
</p>
<p><span class="Bold">775 mg</span></p>
<p>Pragmaâ„¢
</p>
<p><span class="Bold">Rx only  Rev 0514 PBL-002</span></p>
<div class="Figure">
<a name="f03"></a><img alt="Principal Display Panel
" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4057faf7-6d45-4d9e-90e9-72a546214d04&amp;name=mox02-0001-03.jpg">
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>MOXATAGÂ 		
					</strong><br><span class="contentTableReg">amoxicillin tablet, film coated, extended release</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:58463-002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>amoxicillin</strong> (amoxicillin anhydrous) </td>
<td class="formItem">amoxicillin anhydrous</td>
<td class="formItem">775Â mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>crospovidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C blue no. 2</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>hypromelloses</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>hypromellose acetate succinate 16070722 (3 mm2/s)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>ferric oxide red</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>magnesium stearate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>methacrylic acid - methyl methacrylate copolymer (1:1)</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>cellulose, microcrystalline</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>polyethylene glycol 400</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>polyoxyl 35 castor oil</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>povidone</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>shellac</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>colloidal silicon dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sodium lauryl sulfate</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>talc</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>titanium dioxide</strong></td>
<td class="formItem">Â </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>triethyl citrate</strong></td>
<td class="formItem">Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">blue (blue) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL (OVAL) </td>
<td class="formLabel">Size</td>
<td class="formItem">22mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">MB;111
</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">Â Â Â Â </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:58463-002-30</td>
<td class="formItem">30  in 1 BOTTLE; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">NDA</td>
<td class="formItem">NDA050813</td>
<td class="formItem">07/28/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>Pragma Pharmaceuticals, LLC
							(078813515)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 6/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>a61f4ef4-23bc-4975-abd1-39aef8f3c797</div>
<div>Set id: 4057faf7-6d45-4d9e-90e9-72a546214d04</div>
<div>Version: 3</div>
<div>Effective Time: 20150616</div>
</div>
</div>Â <div class="DistributorName">Pragma Pharmaceuticals, LLC</div></p>
</body></html>
